Juno Therapeutics (NASDAQ:JUNO) is developing next-generation cancer therapies that use a patient's own immune system to find and destroy cancer cells.
Although the company doesn't have any drugs currently on the market, it hopes that a promising drug for adult lymphoblastic leukemia will succeed in mid stage studies and clear the way to an FDA filling in 2017.
Given high response rates to its most advanced drug and a timeline that could mean Juno Therapeutics begins generating sales within two years, investors boosted shares by 12.1% last month. In the following slideshow, I offer up additional insight into Juno Therapeutics intriguing approach and its timeline to commercialization.
Todd Campbell is long Celgene. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool recommends Juno Therapeutics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Juno Therapeutics Stock Cooled Off in December
Juno's year-long rally came to an abrupt halt last month on concerns that it won't be able to catch up to the leaders in CAR-T.
Why 2017 Was a Year to Remember for Juno Therapeutics
The biotech pushed past the loss of its lead drug to show its next-generation drug could fill the void.
Why Juno Therapeutics Stock Fell Last Week
Juno's CAR-T trial results looked pretty good, but a few big issues have investors nervous about the future.